BGMSP Pivots to Fire Safety, Reports $5M Deconsolidation Gain

Ticker: BGMSP · Form: 10-Q · Filed: Nov 13, 2025 · CIK: 1130166

Sentiment: mixed

Topics: Strategic Pivot, Biopharma Exit, Fire Safety, Acquisition, Deconsolidation, Reverse Stock Split, Malaysia Market

Related Tickers: BGMSP, BGMS, 9318.KL

TL;DR

**BGMSP's radical pivot to fire safety is a high-stakes gamble; the $5M deconsolidation gain is a one-time boost, but sustained profitability hinges on the Malaysian acquisition's success.**

AI Summary

Bio Green Med Solution, Inc. (BGMSP) underwent a significant strategic shift in 2025, transitioning from a biopharmaceutical company to a diversified entity focused on fire safety protection and distribution. This change was marked by the liquidation of its wholly-owned UK subsidiary, Cyclacel Limited, on January 24, 2025, resulting in a gain on deconsolidation of approximately $5.0 million. The company also sold its plogosertib (Plogo) clinical program assets for $300,000, with a potential $170,000 milestone payment. A pivotal event was the acquisition of Fitters Sdn. Bhd., a Malaysia-based fire protection company, on September 12, 2025, which introduced product revenue of $81,000 for the three and nine months ended September 30, 2025, compared to zero in the prior year. Despite this new revenue stream, the company reported a net loss of $2.387 million for the nine months ended September 30, 2025, an improvement from the $8.160 million net loss in the same period of 2024. Operating expenses decreased to $7.426 million for the nine months ended September 30, 2025, down from $10.219 million in 2024, primarily due to a reduction in research and development costs from $5.775 million to $895,000. Cash and cash equivalents increased to $3.838 million as of September 30, 2025, from $3.137 million at December 31, 2024, largely driven by $5.523 million in financing activities.

Why It Matters

This strategic pivot is a make-or-break moment for BGMSP, fundamentally altering its risk profile and growth trajectory. For investors, the shift from high-risk biopharma R&D to a more stable, albeit potentially lower-growth, fire safety business in Malaysia demands a complete re-evaluation of the company's intrinsic value and competitive landscape. Employees of the former biopharma segment face uncertainty, while those joining from Fitters Sdn. Bhd. are now part of a Nasdaq-listed entity. Customers of Fitters Sdn. Bhd. may see expanded access to capital for innovation. The broader market will watch to see if this diversification strategy can successfully transform a struggling biopharma into a viable diversified enterprise, setting a precedent for other micro-cap companies seeking new directions.

Risk Assessment

Risk Level: high — The company has undergone a complete business model transformation, shifting from biopharmaceuticals to fire safety and distribution. This involves significant integration risks with the acquisition of Fitters Sdn. Bhd. and the challenge of establishing a new operational focus, as evidenced by the new product revenue of only $81,000 for the nine months ended September 30, 2025, against a net loss of $2.387 million. The company also reported a deemed dividend on warrant exchange of $1.494 million, indicating potential dilution or complex financial instruments.

Analyst Insight

Investors should exercise extreme caution and conduct thorough due diligence on the newly acquired fire safety business, Fitters Sdn. Bhd., and its market in Malaysia. Monitor future filings closely for revenue growth, profitability, and integration progress of the new segment, as the biopharma assets have largely been liquidated or sold.

Financial Highlights

debt To Equity
N/A
revenue
$81,000
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
-$2,387,000
eps
-$1.31
gross Margin
N/A
cash Position
$3,838,000
revenue Growth
N/A

Revenue Breakdown

SegmentRevenueGrowth
Fire Safety Protection and Distribution$81,000N/A

Key Numbers

Key Players & Entities

FAQ

What was Bio Green Med Solution, Inc.'s primary business focus before September 2025?

Before September 2025, Bio Green Med Solution, Inc. (formerly Cyclacel Pharmaceuticals, Inc.) was primarily engaged in the biopharmaceutical industry, focusing on clinical research programs through its wholly-owned UK subsidiary, Cyclacel Limited.

How did the liquidation of Cyclacel Limited impact BGMSP's financial statements?

The liquidation of Cyclacel Limited on January 24, 2025, led to its deconsolidation from BGMSP's financial results, resulting in a significant gain on deconsolidation of approximately $5.0 million, recorded as other income in the income statement.

What new business segment did Bio Green Med Solution, Inc. enter in 2025?

In September 2025, Bio Green Med Solution, Inc. entered the fire safety protection and distribution sector through the acquisition of Fitters Sdn. Bhd., a Malaysia-based company specializing in fire protection products and services.

What were BGMSP's revenues from fire safety products for the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, Bio Green Med Solution, Inc. reported product revenue from fire safety of $81,000, a new revenue stream compared to zero in the same period of 2024.

Who is Datuk Dr. Doris Wong Sing Ee and what was her role in BGMSP's recent developments?

Datuk Dr. Doris Wong Sing Ee is an investor who, on February 11, 2025, purchased 1,000,000 shares of Series C Convertible Preferred Stock and 1,745,262 shares of Series D Convertible Preferred Stock from David E. Lazar, ultimately owning 810,952 shares of BGMSP's Common Stock after conversion.

What was the impact of the reverse stock splits on BGMSP's common stock?

Bio Green Med Solution, Inc. effected a one-for-sixteen reverse stock split on May 12, 2025, and a further one-for-fifteen reverse stock split on July 7, 2025. All share and per share data in the financial statements have been retrospectively adjusted to reflect these changes.

What happened to the plogosertib (Plogo) clinical program assets?

On October 6, 2025, Bio Green Med Solution, Inc. entered into an Asset Purchase Agreement with Tethra Biosciences Inc. to sell all patent rights related to Plogo for a purchase price of $300,000, plus a potential milestone payment of $170,000.

How did BGMSP's net loss change from Q3 2024 to Q3 2025?

Bio Green Med Solution, Inc.'s net loss for the three months ended September 30, 2025, was $988,000, an improvement from a net loss of $1.957 million for the three months ended September 30, 2024.

What are the key risks associated with Bio Green Med Solution, Inc.'s current business strategy?

Key risks include the successful integration and performance of the newly acquired Fitters Sdn. Bhd. in the fire safety sector, the challenges of operating in a new market (Malaysia), and the ability to generate sustained profitability from this new business model following the complete exit from biopharmaceutical R&D.

Where is Bio Green Med Solution, Inc. headquartered after its strategic shift?

Following its strategic shift and the acquisition of Fitters Sdn. Bhd., Bio Green Med Solution, Inc. is now headquartered in Kuala Lumpur, Malaysia, at Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, 59200.

Risk Factors

Industry Context

Bio Green Med Solution, Inc. is transitioning into the fire safety protection and distribution industry. This sector is characterized by established players and requires adherence to stringent safety regulations and product standards. Growth in this industry is often driven by construction, infrastructure development, and increasing awareness of safety protocols.

Regulatory Implications

The company's new focus on fire safety exposes it to industry-specific regulations concerning product safety, manufacturing standards, and distribution channels. Compliance with these regulations is crucial to avoid penalties and maintain market access.

What Investors Should Do

  1. Monitor the integration and performance of Fitters Sdn. Bhd. to assess the success of the strategic pivot into fire safety.
  2. Evaluate the company's ability to generate positive operating cash flow and reduce its reliance on financing activities.
  3. Assess the long-term viability and competitive positioning of the company within the fire safety market.
  4. Analyze future filings for trends in operating expenses, particularly R&D, and their impact on profitability.

Key Dates

Glossary

Deconsolidation
The process of removing a subsidiary from a parent company's consolidated financial statements, typically occurring when control is lost. (Explains the $5.0 million gain recognized from the liquidation of Cyclacel Limited.)
Plogosertib (Plogo)
A clinical program asset that the company sold, indicating a divestiture from its biopharmaceutical operations. (Represents a step in the company's strategic pivot away from its former core business.)
Securities Purchase Agreement
A contract between a buyer and a seller for the purchase and sale of securities. (Details the transactions involving preferred stock with investors like David E. Lazar and Datuk Dr. Doris Wong Sing Ee.)
Common Stock
The basic form of ownership in a corporation, representing voting rights and a claim on residual assets. (The number of outstanding common shares increased significantly due to conversions and acquisitions, impacting EPS.)
Warrant Exchange
An event where outstanding warrants are exchanged, potentially resulting in a non-cash charge like a deemed dividend. (Led to a $1.494 million non-cash charge impacting net loss applicable to common shareholders.)

Year-Over-Year Comparison

Compared to the prior year, Bio Green Med Solution, Inc. has significantly reduced its net loss from $8.160 million to $2.387 million for the nine months ended September 30, 2025, primarily due to a drastic cut in R&D expenses from $5.775 million to $895,000. This reflects the company's strategic shift away from biopharmaceuticals. A new revenue stream from fire safety products has been introduced, though it generated only $81,000 in the period. Cash reserves have increased, supported by substantial financing activities, while the number of outstanding common shares has surged due to conversions and acquisitions.

Filing Stats: 4,824 words · 19 min read · ~16 pages · Grade level 16.5 · Accepted 2025-11-13 17:01:03

Key Financial Figures

Filing Documents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION: Item 1.

Financial Statements

Financial Statements: F-1 Balance Sheets as of September 30, 2025 and December 31, 2024 (unaudited) F-1 F-2 Consolidated Statements of Comprehensive Loss F-3 F-4 F-5

Notes to Financial Statements (Unaudited)

Notes to Financial Statements (Unaudited) F-6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 4 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 11 Item 4.

Controls and Procedures

Controls and Procedures 11

- OTHER INFORMATION

PART II - OTHER INFORMATION: Item 1.

Legal Proceedings

Legal Proceedings 11 Item 1A.

Risk Factors

Risk Factors 12 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 14 Item 3. Defaults Upon Senior Securities 14 Item 4. Mine Safety Disclosures 14 Item 5. Other Information 14 Item 6. Exhibits 14 SIGNATURE PAGE 15 2 Recent Developments In December 2024, Bio Green Med Solution, Inc., a Delaware corporation ("BGMS" or the "Company") announced that it was in the process of exploring and reviewing strategic alternatives on an expedited basis in order to preserve the Company's cash, including a potential transaction with investor, David E. Lazar of Activist Investing, LLC ("Lazar"). The Company's Board of Directors (the "Board") reviewed a range of appropriate strategies to realize value from its assets. The Board directed management to reduce operating costs, which included the liquidation of the Company's wholly-owned United Kingdom subsidiary, Cyclacel Limited ("Subsidiary"), while such alternatives were being explored. On January 2, 2025, the Company entered into a securities purchase agreement with Lazar, pursuant to which he agreed to purchase from the Company, 1,000,000 shares of Series C Convertible Preferred Stock and 2,100,000 shares of Series D Convertible Preferred Stock of Cyclacel at a purchase price of $1.00 per share for aggregate gross proceeds of $3.1 million, subject to the terms and conditions of the securities purchase agreement (together, the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock are the "Securities"). The proceeds of the transaction were used to settle outstanding liabilities of the Company and other general corporate and operating purposes. On February 11, 2025, investor Lazar, who was serving as the Company's interim Chief Executive Officer and Secretary, entered into a securities purchase agreement (the "Purchase Agreement") with an investor, Datuk Dr. Doris Wong Sing Ee (the "Investor") pursuant to which the Investor agreed to purchase all 1,000,000 shares

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing